Osteoporotic Conditions Influence the Activity of Adipose-Derived Stem Cells

Overview

Journal Tissue Eng Regen Med

Date 2020 Sep 18

PMID 32946062

Citations 11

Authors

Jeong Seop Park

Jiyuan Piao

Gabee Park

Kyung Sang Yoo

Hyun Sook Hong

Affiliations

Soon will be listed here.

Abstract

Background: Estrogen deficiency decreases bone density and increases the risk of osteoporosis and fracture, thereby necessitating reconstruction of bone regeneration. As bone marrow mesenchymal stem cell (BMSCs) lose viability and differentiation potential under osteoporotic conditions, it is impossible to use autologous BMSCs for osteoporosis treatment. As an alternative, adipose-derived stem cells (ADSCs) may serve as the source of therapeutic cells.

Method: We evaluated the effects of osteoporosis on the functional characteristics of ADSCs. Osteoporosis was induced in ovariectomy (OVX) rat model, and the ADSCs from Sham and OVX groups were cultured and analyzed comparatively.

Results: As a result, the viability was higher for the ADSCs from Sham group than those from OVX group. The analysis of the paracrine potential of ADSCs revealed the elevated levels of inflammatory and cellular senescence factors in the ADSCs from OVX group. The ADSCs from OVX group had much higher differentiation potential into adipocytes than those from the Sham group. Osteoporotic environment had no effect on the osteogenic potential of ADSCs.

Conclusion: Osteoporosis may reduce the activity and influence immune response of ADSCs by modulating paracrine action and adipogenic potential. These characteristics of ADSCs should be given consideration for therapeutic purpose.

Citing Articles

Association between Donor Age and Osteogenic Potential of Human Adipose Stem Cells in Bone Tissue Engineering.

Sattar M, Lingens L, Guillaume V, Goetzl R, Beier J, Ruhl T Curr Issues Mol Biol. 2024; 46(2):1424-1436.

PMID: 38392210 PMC: 10887920. DOI: 10.3390/cimb46020092.

FGF2/HGF priming facilitates adipose-derived stem cell-mediated bone formation in osteoporotic defects.

Park J, Kim D, Hong H Heliyon. 2024; 10(2):e24554.

PMID: 38304814 PMC: 10831751. DOI: 10.1016/j.heliyon.2024.e24554.

Preconditioning with Substance P Restores Therapeutic Efficacy of Aged ADSC by Elevating TNFR2 and Paracrine Potential.

Piao J, Cho H, Park J, Yoo K, Jeong I, Hong H Biology (Basel). 2023; 12(12).

PMID: 38132284 PMC: 10740808. DOI: 10.3390/biology12121458.

Priming with a Combination of FGF2 and HGF Restores the Impaired Osteogenic Differentiation of Adipose-Derived Stem Cells.

Park J, Kim D, Hong H Cells. 2022; 11(13).

PMID: 35805126 PMC: 9265418. DOI: 10.3390/cells11132042.

Knockdown of PDX1 enhances the osteogenic differentiation of ADSCs partly via activation of the PI3K/Akt signaling pathway.

Liu F, Chen G, Fan L J Orthop Surg Res. 2022; 17(1):107.

PMID: 35183219 PMC: 8858563. DOI: 10.1186/s13018-021-02825-4.

References

Whyte M, Wenkert D, Clements K, McAlister W, Mumm S . Bisphosphonate-induced osteopetrosis. N Engl J Med. 2003; 349(5):457-63. DOI: 10.1056/NEJMoa023110. View

Ponnapakkam T, Katikaneni R, Sakon J, Stratford R, Gensure R . Treating osteoporosis by targeting parathyroid hormone to bone. Drug Discov Today. 2013; 19(3):204-8. PMC: 3979969. DOI: 10.1016/j.drudis.2013.07.015. View

Zheng S, Vrindts Y, Lopez M, De Groote D, Zangerle P, Collette J . Increase in cytokine production (IL-1 beta, IL-6, TNF-alpha but not IFN-gamma, GM-CSF or LIF) by stimulated whole blood cells in postmenopausal osteoporosis. Maturitas. 1997; 26(1):63-71. DOI: 10.1016/s0378-5122(96)01080-8. View

Fliefel R, Troltzsch M, Kuhnisch J, Ehrenfeld M, Otto S . Treatment strategies and outcomes of bisphosphonate-related osteonecrosis of the jaw (BRONJ) with characterization of patients: a systematic review. Int J Oral Maxillofac Surg. 2015; 44(5):568-85. DOI: 10.1016/j.ijom.2015.01.026. View

Calabrese G, Giuffrida R, Forte S, Fabbi C, Figallo E, Salvatorelli L . Human adipose-derived mesenchymal stem cells seeded into a collagen-hydroxyapatite scaffold promote bone augmentation after implantation in the mouse. Sci Rep. 2017; 7(1):7110. PMC: 5541101. DOI: 10.1038/s41598-017-07672-0. View

Ren C, Kumar S, Chanda D, Chen J, Mountz J, Ponnazhagan S . Therapeutic potential of mesenchymal stem cells producing interferon-alpha in a mouse melanoma lung metastasis model. Stem Cells. 2008; 26(9):2332-8. PMC: 2940717. DOI: 10.1634/stemcells.2008-0084. View

Ji M, Yu Q . Primary osteoporosis in postmenopausal women. Chronic Dis Transl Med. 2017; 1(1):9-13. PMC: 5643776. DOI: 10.1016/j.cdtm.2015.02.006. View

Cenci S, Weitzmann M, Roggia C, Namba N, Novack D, Woodring J . Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha. J Clin Invest. 2000; 106(10):1229-37. PMC: 381439. DOI: 10.1172/JCI11066. View

Wagner W, Wein F, Seckinger A, Frankhauser M, Wirkner U, Krause U . Comparative characteristics of mesenchymal stem cells from human bone marrow, adipose tissue, and umbilical cord blood. Exp Hematol. 2005; 33(11):1402-16. DOI: 10.1016/j.exphem.2005.07.003. View

10.

Ebraheim N, Elgafy H, Xu R . Bone-graft harvesting from iliac and fibular donor sites: techniques and complications. J Am Acad Orthop Surg. 2001; 9(3):210-8. DOI: 10.5435/00124635-200105000-00007. View

11.

Zhu Y, Liu T, Song K, Fan X, Ma X, Cui Z . Adipose-derived stem cell: a better stem cell than BMSC. Cell Biochem Funct. 2008; 26(6):664-75. DOI: 10.1002/cbf.1488. View

12.

Watts N, Diab D . Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab. 2010; 95(4):1555-65. DOI: 10.1210/jc.2009-1947. View

13.

Zhao R . Immune regulation of bone loss by Th17 cells in oestrogen-deficient osteoporosis. Eur J Clin Invest. 2013; 43(11):1195-202. DOI: 10.1111/eci.12158. View

14.

DAmelio P, Grimaldi A, Di Bella S, Brianza S, Cristofaro M, Tamone C . Estrogen deficiency increases osteoclastogenesis up-regulating T cells activity: a key mechanism in osteoporosis. Bone. 2008; 43(1):92-100. DOI: 10.1016/j.bone.2008.02.017. View

15.

Sophocleous A, Idris A . Rodent models of osteoporosis. Bonekey Rep. 2015; 3:614. PMC: 4388108. DOI: 10.1038/bonekey.2014.109. View

16.

Baroncelli G, Bertelloni S . The use of bisphosphonates in pediatrics. Horm Res Paediatr. 2014; 82(5):290-302. DOI: 10.1159/000365889. View

17.

Neer R, Arnaud C, Zanchetta J, Prince R, Gaich G, Reginster J . Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001; 344(19):1434-41. DOI: 10.1056/NEJM200105103441904. View

18.

Shen L, Xie X, Su Y, Luo C, Zhang C, Zeng B . Parathyroid hormone versus bisphosphonate treatment on bone mineral density in osteoporosis therapy: a meta-analysis of randomized controlled trials. PLoS One. 2011; 6(10):e26267. PMC: 3192168. DOI: 10.1371/journal.pone.0026267. View

19.

Lelovas P, Xanthos T, Thoma S, Lyritis G, Dontas I . The laboratory rat as an animal model for osteoporosis research. Comp Med. 2008; 58(5):424-30. PMC: 2707131. View

20.

Bajada S, Mazakova I, Richardson J, Ashammakhi N . Updates on stem cells and their applications in regenerative medicine. J Tissue Eng Regen Med. 2008; 2(4):169-83. DOI: 10.1002/term.83. View